Commercial antibodies against varying proteins are often not optimal for identification of proteins in their amyloid fibril forms. Reasons can be the different conformation but also a variety of modifications like N- or C-terminal truncation. Therefore, development of own monoclonal antibodies against amyloid fibril proteins may be advantageous. This chapter gives suggestions of how to be successful in such approaches.
Keywords: Amyloid; Degraded amyloid; Fibril; Hybridoma; Immunohistochemistry; Transthyretin; Western blot.